Delcath Systems, Inc.
- DCTH
- NASDAQ
- Medical devices
- Interventional Oncology
- Liver Cancer Treatment (HEPZATO)
$14.08
Today −4.93%Quote Oct 16, 2026, 08:00 PM UTC
−13.35%over the last month
Max drawdown −14.1%From 1-month high −14.1%3 months +11.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$488.6M
Quote Oct 16
Next earnings
Nov 3
Expected, not confirmed
Analyst target
$24.50
+74.0% from here
Floor
$13.83
1.8% below price
Where the price sits
11 analysts
Analyst range, low to high
$17.00$32.00
- Price $14.08
- Resistance $14.60
- Consensus $24.50
The price is just above its floor. Analysts' average target sits about 74% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about DCTHPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Medical devices
Employees
156